In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline  by Choudhury, S. et al.
LETTER TO THE EDITOR BACTERIOLOGYIn vitro susceptibilities of clinical isolates of
carbapenemase-producing
Enterobacteriaceae to fosfomycin and
tigecyclineS. Choudhury, J. L. W. Yeng and P. U. Krishnan
Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore
Original Submission: 30 May 2015; Accepted: 4 June 2015
Editor: D. Raoult
Article published online: 16 June 2015This work was presented in part as a poster at the European Society
of Clinical Microbiology and Infectious Diseases Conference on
Reviving Old Antibiotics, Vienna, Austria, 22–24 October 2014.
Corresponding author: S. Choudhury, Department of Laboratory
Medicine, 11 Jalan Tan Tock Seng, Tan Tock Seng Hospital, Singapore
308433, Singapore
E-mail: drsaugata@yahoo.comTABLE 1. In vitro susceptibility of CPE isolates to fosfomycin
and tigecycline







Klebsiella pneumoniae (17) blaNDM-1 (6) 6 1
blaKPC (4) 4 3
blaIMP-1 (4) 2 2
blaOXA-48-like (3) 2 3
Escherichia coli (10) blaNDM-1 (9) 9 9
blaKPC (1) 1 1
Enterobacter cloacae (6) blaNDM-1 (4) 4 2
blaIMP-1 (2) 2 2
Proteus mirabilis (2) blaOXA-48-like 2 0
Morganella spp. (1) blaNDM-1 0 1
Total (36) 32 (88.8%) 24 (66.6%)
CPE, carbapenemase-producing Enterobacteriaceae.The global spread of carbapenemase-producing Enter-
obacteriaceae (CPE) represents a serious clinical challenge due to
their high transmissibility and limited treatment options [1].
Singapore has recently reported increasing numbers of
carbapenem-resistant Enterobacteriaceae [2]. Fosfomycin is often
used asmonotherapy for urinary tract infections, and tigecycline is
frequently included in combination therapy for infections at other
sites caused by multidrug-resistant organisms; these antibiotics
resist degradation by carbapenemases by virtue of possessing
targets that are unaffected by these enzymes, namely enolpyr-
uvate transferase and 30S ribosomal subunit, which are required
for mucopeptide and protein synthesis, respectively. While fos-
fomycin is an old antibiotic commonly used for as monotherapy
for uncomplicated urinary tract infections, tigecycline is a rela-
tively novel drug approved by the US Food and Drug Adminis-
tration for skin and soft tissue infection (SSTI) and abdominal
infections with negligible excretion in urine [3]. Both drugs,
however, do not have signiﬁcant bactericidal activity, either as
monotherapy or in combination therapy for bacteraemia.
The present study was performed in a 1500-bed, predomi-
nantly geriatric care hospital in Singapore. Thirty-six consecutive
CPE isolates obtained from urine, blood and SSTI samples from
September 2012 to March 2015 were selected for this study
(Table 1). A reﬂex testing protocol including phenotypic and
genotypic tests was used for identiﬁcation and conﬁrmation of the
carbapenemase-encoding genes in these isolates (http://eccmid.
meetingexpert.net/ECCMID_546/poster_123747/program.aspx/Clinical Microbiology and Infection © 2015 European Society of Canchor123747). Disc diffusion tests using 15 μg tigecycline and
200 μg fosfomycin plus 50 μg glucose-6-phosphate discs (Oxoid,
Basingstoke, UK) were performed on these isolates according to
the guidelines of the Clinical and Laboratory Standards Institute
(CLSI) [4]. In the absence of CLSI breakpoints, the European
Committee on Antimicrobial Susceptibility Testing interpretive
criterion (http://www.eucast.org/clinical_breakpoints/.Accessed)
was used for tigecycline; for fosfomycin, CLSI breakpoints appli-
cable to Escherichia coli were extrapolated to all coliforms.
The majority of the clinical isolates were from a urinary
source (72.3%), while the remainder were isolated from SSTI
(19.4%) and bloodstream (8.3%) infections. Twenty (56%) out
of the thirty-six isolates were genotyped as blaNDM-1, with the
remainder were identiﬁed as blaIMP-1 (16%), blaOXA-48-like
(14%) and blaKPC (14%). The majority (88.8%) of the CPE iso-
lates were susceptible to fosfomycin, while approximately two
thirds (66.6%) were susceptible to tigecycline. Of note, all the
urinary isolates were susceptible to fosfomycin, while 71.0% of
the SSTI isolates were susceptible to tigecycline.
Fosfomycin and tigecycline represent potential therapeutic
options for site-speciﬁc infections caused by CPE. These anti-
microbials could be considered as monotherapy as an alterna-
tive to the commonly used anti-CPE drugs like colistin plus
aminoglycosides [5], particularly in a geriatric population.
Though fosfomycin and tigecycline have elevated minimum
inhibitory concentrations for genera intrinsically resistant to
colistin (Proteeae tribe and Serratia spp.), they could also be tried
as antibiotics of last resort for site-speciﬁc infections caused by
such bacteria. Furthermore, unlike colistin, they possess activity
against Gram-positive bacteria and are potentially useful in
polymicrobial infections which include CPE. This study is one of
the few where susceptibility against fosfomycin and tigecycline
was tested against clinical isolates of CPE harbouring a diverse
spectrum of class A, B and D carbapenemases.Clin Microbiol Infect 2015; 21: e75–e76
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.06.005
e76 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIBecause susceptibility testing for fosfomycin and tigecycline
is not routinely performed in many laboratories, we hope that
these data can be used by hospitals to select an empiric option
for uncomplicated lower urinary tract infections or SSTI caused
by CPE in preference to colistin plus aminoglycosides.
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